Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Research overview Product Overview Tirzepatide is a modified peptide investigated in controlled laboratory assays of GIPR and GLP-1R signaling
Retatrutide: The Triple Agonist Revolution Retatrutide represents a groundbreaking approach to metabolic research as a first-in-class triple agonist medication developed by Eli Lilly
I was approved within hours
These models help scientists investigate how peptide-based signals influence different biological pathways in controlled experimental conditions
Quality Control Center (CNAS)ISO/IEC 17025:2017 The above laboratory has been assessed by CNAS and found to comply with the requirements of ISO/IEC 17025:2017 General requirements for the competence of testing and calibration laboratories
US$ 24.84
US$ 29.04
US$ 21.93
US$ 21.76
